drugset / Trial / NCT03700359
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized, open-label and active controlled phase II study. It plans to enroll 60 subjects with extensive stage small cell lung cancer (ES-SCLC). All subjects will be assigned randomly to the experimental arm or control arm. The primary endpoints would be overall survival and progression-free survival.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2020-11-29
- Completion
- 2021-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Background | Etoposide | Small molecule | 60 mg/m2 | Intravenous |
| Background | Lobaplatin | Small molecule | 30 mg/m2 | Intravenous |